107 related articles for article (PubMed ID: 34609565)
21. SMARCB1 Loss in Poorly Differentiated Chordomas Drives Tumor Progression.
Walhart TA; Vacca B; Hepperla AJ; Hamad SH; Petrongelli J; Wang Y; McKean EL; Moksa M; Cao Q; Yip S; Hirst M; Weissman BE
Am J Pathol; 2023 Apr; 193(4):456-473. PubMed ID: 36657718
[TBL] [Abstract][Full Text] [Related]
22. A Case of SMARCB1-Deficient Sinonasal Carcinoma With Clear Cell Morphology.
Tamaki T; Teruya K; Hirakawa H; Tomita M; Wada N
Cureus; 2024 May; 16(5):e59684. PubMed ID: 38836164
[TBL] [Abstract][Full Text] [Related]
23. SMARCB1 (INI1) Deficient Tumours of the Uterine Cervix: Report of Two Cases, Including One Associated With an NTRK Fusion.
Razack R; Butt JL; Hostein I; Velasco V; Croce S; Olory C; Fu L; Foulkes WD; McCluggage WG
Int J Gynecol Pathol; 2024 Jan; ():. PubMed ID: 38289183
[TBL] [Abstract][Full Text] [Related]
24. SMARCB1 expression is a novel diagnostic and prognostic biomarker for osteosarcoma.
Guo T; Wei R; Dean DC; Hornicek FJ; Duan Z
Biosci Rep; 2022 Jan; 42(1):. PubMed ID: 34984436
[TBL] [Abstract][Full Text] [Related]
25. SMARCB1/INI1-deficient primary lung carcinoma with hepatic metastasis.
Rickard JA; Burr ML; Williams B; Murugasu A; Fellowes A; John T; Christie M
Pathology; 2022 Oct; 54(6):817-820. PubMed ID: 35177248
[No Abstract] [Full Text] [Related]
26. Non-Clear Cell Renal Cell Carcinomas: From Shadow to Light.
Albiges L; Flippot R; Rioux-Leclercq N; Choueiri TK
J Clin Oncol; 2018 Oct; ():JCO2018792531. PubMed ID: 30372389
[TBL] [Abstract][Full Text] [Related]
27. Radiation Therapy for the Management of Renal Medullary Carcinoma: A Multi-Case Study.
Mbilinyi RH; Msaouel P; Rao P; Karam JA; Tannir NM; Tang C
Clin Genitourin Cancer; 2024 Jun; 22(3):102065. PubMed ID: 38556389
[No Abstract] [Full Text] [Related]
28. [Research progresses of INI1-deficient tumors in children].
Zhang SH; Su Y
Zhonghua Er Ke Za Zhi; 2024 Jan; 62(1):82-86. PubMed ID: 38154984
[TBL] [Abstract][Full Text] [Related]
29. Acquired cystic disease associated renal cell carcinoma: A clinicopathologic and molecular study of 31 tumors.
Palathingal Bava E; Sanfrancesco JM; Alkashash A; Favazza L; Aldilami A; Williamson SR; Cheng L; Idrees MT; Al-Obaidy KI
Hum Pathol; 2024 Jun; 149():48-54. PubMed ID: 38862094
[TBL] [Abstract][Full Text] [Related]
30. Molecularly Defined Thoracic Neoplasms.
Roden AC
Adv Anat Pathol; 2024 Mar; ():. PubMed ID: 38501690
[TBL] [Abstract][Full Text] [Related]
31. SMARCB1/INI1-deficient undifferentiated carcinoma of the ileum with rhabdoid features: A case report.
Duan T; Wang H; Jin Y
Asian J Surg; 2024 Jun; ():. PubMed ID: 38908976
[No Abstract] [Full Text] [Related]
32. Synergistic action of WDR5 and HDM2 inhibitors in SMARCB1-deficient cancer cells.
Florian AC; Woodley CM; Wang J; Grieb BC; Slota MJ; Guerrazzi K; Hsu CY; Matlock BK; Flaherty DK; Lorey SL; Fesik SW; Howard GC; Liu Q; Weissmiller AM; Tansey WP
NAR Cancer; 2022 Mar; 4(1):zcac007. PubMed ID: 35252869
[TBL] [Abstract][Full Text] [Related]
33. Sarcomatoid cholangiocarcinoma in the common bile duct with loss of SMARCB1 protein expression: A rare case report.
Yao J; Wang J; Liu H; Yin H
Asian J Surg; 2024 Jun; ():. PubMed ID: 38906713
[No Abstract] [Full Text] [Related]
34. Immunotherapy in SMARCB1 (INI-1)-deficient sinonasal carcinoma: Two case reports.
Zhang L; Gao AX; He YL; Xu MJ; Lu HJ
World J Clin Cases; 2023 Nov; 11(32):7911-7919. PubMed ID: 38073679
[TBL] [Abstract][Full Text] [Related]
35. Molecular Genetics of Renal Cell Tumors: A Practical Diagnostic Approach.
Alaghehbandan R; Perez Montiel D; Luis AS; Hes O
Cancers (Basel); 2019 Dec; 12(1):. PubMed ID: 31905821
[TBL] [Abstract][Full Text] [Related]
36. Loss of SWI/SNF complex expression in undifferentiated renal carcinoma in acquired cystic kidney.
Kojima F; Ueda Y; Matsuzaki I; Hara I; Murata SI
Pathol Int; 2018 Apr; ():. PubMed ID: 29671925
[No Abstract] [Full Text] [Related]
37. Special Issue Editorial: Emerging Therapies in Renal Cell Carcinoma: The Road to a Cure?
Campbell MT; Zhang T
Cancers (Basel); 2023 Nov; 15(21):. PubMed ID: 37958435
[TBL] [Abstract][Full Text] [Related]
38. SMARCB1 regulates the hypoxic stress response in sickle cell trait.
Soeung M; Perelli L; Chen Z; Dondossola E; Ho IL; Carbone F; Zhang L; Khan H; Le CN; Zhu C; Peoples MD; Feng N; Jiang S; Zacharias NM; Minelli R; Shapiro DD; Deem AK; Gao S; Cheng EH; Lucchetti D; Walker CL; Carugo A; Giuliani V; Heffernan TP; Viale A; Tannir NM; Draetta GF; Msaouel P; Genovese G
Proc Natl Acad Sci U S A; 2023 May; 120(21):e2209639120. PubMed ID: 37186844
[TBL] [Abstract][Full Text] [Related]
39. Systemic Treatment for Advanced and Metastatic Non-Clear Cell Renal Cell Carcinoma: Examining Modern Therapeutic Strategies for a Notoriously Challenging Malignancy.
Drobner J; Portal D; Runcie K; Yang Y; Singer EA
J Kidney Cancer VHL; 2023; 10(3):37-60. PubMed ID: 37789902
[TBL] [Abstract][Full Text] [Related]
40. [SMARCB1(INI1)-deficient renal cell carcinoma: medullary and beyond : Evolving concepts].
Agaimy A; Hartmann A
Pathologe; 2021 Nov; 42(6):571-577. PubMed ID: 34609565
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
